HAE longThis set up looks really bullish. will be playing both gaps to the upside. $80c 3/18/2022 @3.85 could pay big time.
2.50USD
115.40 MUSD
1.17 BUSD
50.29 M
About Haemonetics Corporation
Sector
Industry
CEO
Christopher A. Simon
Website
Headquarters
Boston
Employees (FY)
3.03 K
Founded
1971
ISIN
US4050241003
FIGI
BBG000C7TF41
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
$HAE long$HAE forming a falling wedge approaching key support with RSI divergence on major timeframes, looks due for a bounce here. I like entry here with tight stop, 1 or 2 month time at least.
Haemonetics Receives FDA Clearance For NexSys PCS® With Persona(HAE: Haemonetics Corporation
2020-10-03 20:36:00
Haemonetics Receives FDA Clearance For NexSys PCS® With Persona(TM) Technology
HAEMONETICS! Haemonetics may correct at $100.80. In the long term, it will grow after the correction.
Haemonetics Reported First Quarter Fiscal 2021 Financial ResultsHaemonetics Reported First Quarter Fiscal 2021 Financial Results
themarketsignal.com
RSI of Haemonetics Corporation (NYSE:HAE) is 19.96 and the stock looks bullish. The company reported financial results for first quarter of fiscal 2021. In Q1-21 the company reported $196 million revenue, decreasin
HAE Shortbroke below daily support at 83.27, target 3/20 low (took position thinking i'd target the 3/18 low, but when looking at when i got home see that has such a long wick i think it's a stretch). SL just above the ~87.05 level that provided support over the lsat month
HAE. Price near support line$HAE - HAEMONETICS CORP. Engaged in blood donation activities. On the daily charts, the paper has reached a good level of support at $83. Starting from 19.06 the volume is significantly above the average, the RSI indicator came out of the oversold zone and shows a buy signal on the daily timeframe.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HAE is 83.27 USD — it has decreased by 0.23% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Haemonetics Corporation stocks are traded under the ticker HAE.
Haemonetics Corporation is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
HAE stock is 0.29% volatile and has beta coefficient of 0.65. Check out the list of the most volatile stocks — is Haemonetics Corporation there?
One year price forecast for Haemonetics Corporation has a max estimate of 115.00 USD and a min estimate of 88.00 USD.
HAE earnings for the last quarter are 0.99 USD per share, whereas the estimation was 0.89 USD resulting in a 11.51% surprise. The estimated earnings for the next quarter are 0.94 USD per share. See more details about Haemonetics Corporation earnings.
Haemonetics Corporation revenue for the last quarter amounts to 318.18 M USD despite the estimated figure of 313.15 M USD. In the next quarter revenue is expected to reach 320.84 M USD.
Yes, you can track Haemonetics Corporation financials in yearly and quarterly reports right on TradingView.
HAE stock has fallen by 3.15% compared to the previous week, the month change is a 8.13% rise, over the last year Haemonetics Corporation has showed a 2.04% decrease.
HAE net income for the last quarter is 31.24 M USD, while the quarter before that showed 24.91 M USD of net income which accounts for 25.43% change. Track more Haemonetics Corporation financial stats to get the full picture.
Today Haemonetics Corporation has the market capitalization of 4.24 B, it has increased by 1.37% over the last week.
No, HAE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HAE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Haemonetics Corporation stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 3.03 K employees. See our rating of the largest employees — is Haemonetics Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Haemonetics Corporation technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Haemonetics Corporation stock shows the buy signal. See more of Haemonetics Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Haemonetics Corporation future price: according to them, HAE price has a max estimate of 115.00 USD and a min estimate of 88.00 USD. Read a more detailed Haemonetics Corporation forecast: see what analysts think of Haemonetics Corporation and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Haemonetics Corporation EBITDA is 293.56 M USD, and current EBITDA margin is 22.29%. See more stats in Haemonetics Corporation financial statements.